Brent Nall, MD
Gynecology · Lubbock, TXNPI 1043298094
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 130 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AbbVie at 26.7% of the total. Reporting peaked in 2021 at $542 and has fallen 64.4% since, to $193 in 2025.
Across 130 payments — averaging $19.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$664
- Daiichi Sankyo Inc.$219
- Sumitomo Pharma America, Inc.$203
- Amgen$182
- Bayer$182
- Exeltis, USA Inc.$179
- plus $864 from 17 others
What the payments were for
- Food & beverage$2,491100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 30 | $664 |
| Daiichi Sankyo Inc. | 11 | $219 |
| Sumitomo Pharma America, Inc. | 8 | $203 |
| Amgen | 23 | $182 |
| Bayer | 10 | $182 |
| Exeltis, USA Inc. | 3 | $179 |
| Femselect Inc. | 1 | $107 |
| Radius Health, Inc. | 6 | $98 |
| Astellas Pharma US Inc | 6 | $98 |
| Therapeuticsmd, Inc. | 6 | $91 |
| Vertical Pharmaceuticals, LLC | 5 | $74 |
| Mayne Pharma Commercial LLC | 3 | $65 |
| Coloplast | 2 | $44 |
| Osiris Therapeutics Inc. | 1 | $42 |
| Lupin Inc. | 3 | $41 |
| Merck | 3 | $39 |
| Smith+Nephew | 1 | $35 |
| Pfizer | 2 | $30 |
| Caldera Medical, Inc | 2 | $28 |
| Medtronic | 1 | $24 |
| Hologic Sales And Service, LLC | 1 | $21 |
| Avion Pharmaceuticals | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,491 in reported general payments places this provider in the 70th percentile of 161 gynecology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 30 | $19,472 |
| Estradiol | 401 | $17,833 |
| PremarinEstrogens, Conjugated | 18 | $9,800 |
| ImvexxyEstradiol | 12 | $4,612 |
| Estradiol (Twice Weekly)Estradiol | 36 | $4,340 |
| YuvafemEstradiol | 14 | $2,335 |
| Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet | 21 | $1,942 |
| DottiEstradiol | 16 | $1,860 |
| Estradiol (Once Weekly)Estradiol | 12 | $1,542 |
| Raloxifene Hcl | 14 | $927 |
| Medroxyprogesterone Acetate | 51 | $688 |
| ValacyclovirValacyclovir Hcl | 15 | $615 |
| Solifenacin Succinate | 11 | $557 |
| Ibandronate Sodium | 17 | $516 |
| Betamethasone Dipropionate | 19 | $347 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $98 | $19,47230 claims |
| PfizerPremarin | $30 | $9,80018 claims |
| Therapeuticsmd, Inc.Imvexxy | $91 | $4,61212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 161 gynecology providers in Texas.
Other gynecology in Lubbock
- Duncan BurkholderLubbock$3K
- Jennifer OwenLubbock$2K
- Richard FarnamEl Paso$1.2M
- Jessica ShepherdDallas$809K
- Linda LacyEl Paso$627K
- John WhitfieldFort Worth$141K
- Robert ZurawinHouston$61K
- Charles EubankCorpus Christi$51K
- Tiffany JacksonGarland$50K
- Cynthia Chaparro-KruegerAustin$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.